ReviewFrontiers in medicine2017
(A Critical Appraisal of) Classification of Hypereosinophilic Disorders.
Review in Frontiers in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it.
- French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes.Orphanet journal of rare diseases · 2023Guideline
- Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.Frontiers in immunology · 2022Trial
- Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.The Journal of allergy and clinical immunology · 2020Trial
- Refractory Pruritus in End-Stage Prostatic Adenocarcinoma: An Unusual Presentation of A Hypereosinophilic Syndrome.European journal of case reports in internal medicine · 2026Article
- Loeffler endocarditis in hypereosinophilic syndrome, the paradox of absent peripheral eosinophilia: a case report.European heart journal. Case reports · 2025Article
- Paradoxical Use of Benralizumab in Reactive Hypereosinophilia from Toxocariasis and Tuberculosis Co-Infection-Case Report and Literature Review.International journal of molecular sciences · 2025Review
- Primary care physicians play a crucial role in diagnosing and managing rare eosinophilic diseases: HES and EGPA.Frontiers in medicine · 2025Review
- Clinical and immunological biomarkers in hypereosinophilic syndrome: the second step after diagnostic algorithms.Frontiers in medicine · 2025Article
- Steroid-sparing benefits of biologic use in hypereosinophilic syndrome and substantial disease burden across subtypes.Frontiers in allergy · 2025Article
- A unique case of paraneoplastic lymphomatoid Papuloerythroderma of Ofuji with atypical clinical features.JAAD case reports · 2024Article
- Review
- [Hypereosinophilic syndrome, case report and diagnostic approach].Revista medica del Instituto Mexicano del Seguro Social · 2024Article
- The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review.Central-European journal of immunology · 2024Review
- Probable idiopathic hypereosinophilic syndrome: A case report of severe multi-organ eosinophilic involvement in a young male presenting with heart failure.SAGE open medical case reports · 2024Article
- B-cell acute lymphoblastic leukemia associated with hypereosinophilia: a case report and brief literature review.SAGE open medical case reports · 2024Article
- HES and EGPA: Two Sides of the Same Coin.Mayo Clinic proceedings · 2023Review
- Acute necrotizing eosinophilic myocarditis presenting with cardiogenic shock after mRNA booster dose for COVID-19: Case report and review of literature.Journal of cardiology cases · 2023Article
- Eosinophilic granulomatosis with polyangiitis - Advances in pathogenesis, diagnosis, and treatment.Frontiers in medicine · 2023Review
- Management of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach.Frontiers in immunology · 2023Article
- Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes.Allergy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypereosinophilia (HE) is a heterogeneous condition that can be reported in various (namely inflammatory, allergic, infectious, or neoplastic) diseases with distinct pathophysiological pathways. In 1975, Chusid et al. published the first diagnostic criteria of hypereosinophilic syndromes (HES). Over the years, as both basic and clinical knowledge improved, several updates have been suggested, with a focus on better distinguishing isolated or asymptomatic eosinophilia from diseases with specific eosinophil-related organ damage. Moreover, underlying molecular and cellular mechanisms of eosinophilia gradually became the cornerstone of successive attempts to classify HE-related diseases. In 2011, the International Cooperative Working Group on Eosinophil Disorders criteria emerged from a multidisciplinary Working Conference on Eosinophil Disorders and Syndromes, and provided substantial contribution to the clarification of general concepts and definitions in the field of HE. Yet, owing to the low prevalence of HE/HES, to the numerous diseases encompassed in the spectrum of HE-related disorders (with sometimes overlapping phenotypes), many questions are left unanswered (e.g., the need to better standardize the use of modern molecular tools, or the clinical relevance of distinguishing different subtypes of idiopathic HES). Here, we review the current state of knowledge in the fields of classification and diagnosis criteria of HE-related diseases, with emphasis on the analysis of both strengths and weaknesses of present concepts and their usefulness in daily practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.